Bristol Myers Squibb

Bristol-Myers Squibb Company (NYSE: BMY) is a leading global biopharmaceutical company headquartered in New York City. The company was formed in 1989 through the merger of Bristol-Myers Company and Squibb Corporation, with roots dating back to 1858. Bristol-Myers Squibb is focused on discovering, developing and delivering innovative medicines to help patients prevail over serious diseases.

Bristol-Myers Squibb's product portfolio and pipeline span several therapeutic areas including:

• Oncology - with key products like Opdivo for various cancers

• Immunology - including Orencia for rheumatoid arthritis

• Cardiovascular - featuring the anticoagulant Eliquis

• Hematology - with treatments like Revlimid for multiple myeloma

• Fibrosis - developing treatments for liver and lung fibrosis

• Neuroscience - researching therapies for neurodegenerative diseases

As of September 2023, Bristol-Myers Squibb reported USD 46.38 billion in revenue for 2021. The company has a global workforce of approximately 28,000 employees. Bristol-Myers Squibb continues to pursue growth through research and development as well as strategic acquisitions, such as its USD 5.8 billion deal to acquire Mirati Therapeutics in 2023 to expand its oncology portfolio. The company is focused on advancing its pipeline of innovative medicines across key therapeutic areas to address unmet medical needs.